A BSTRACT Introduction: Ultrasound imaging is commonly used during pregnancy to detect potential foetal anomalies. Lamin A (LMNA), a nuclear envelope protein, has been identified as a potential biomarker for predicting adverse pregnancy outcomes. This study investigated the association of obstetrics and foetal ultrasound parameters with maternal serum LMNA during the first and second trimester of pregnancy. Methods: This was a cross-sectional observational study conducted at a teaching institution, Patna, in 2023–2025. The study included 100 singleton pregnancies at 11–24 weeks of gestation. Obstetrics data were collected at first visit of the patients in the Obstetrics and Gynaecology, Outpatient Department. Ultrasound imaging was performed using standard protocols during the first or second trimester to screen congenital anomalies in foetal. Blood sample was withdrawn to estimate the level of serum LMNA. Spearman correlation, Mann-Whitney test and receiver operating characteristics curve (ROC) were used to analyse the results. Results: A significant positive correlation was observed between LMNA and gestational age. Furthermore, maternal age, body mass index, and foetal nuchal translucency (NT) showed significant negative correlations with maternal LMNA levels. Moreover, LMNA levels were decreased in patients with increased NT (>3.5 mm; P < 0.001) as compared to the thinner NT (<3.5 mm). ROC analysis revealed a high diagnostic value of LMNA with NT for predicting anomalies. A significant positive association was also observed between abdominal circumference and maternal serum LMNA levels. Conclusion: The study demonstrated the biomarker potential of maternal serum LMNA for the diagnosis of prenatal congenital heart disease in terms of increased thickness in foetal NT.
Ranjit et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: